Cadrenal Therapeutics, Inc (NASDAQ:CVKD) IPO will take place January, 20 on the NASDAQ exchange under the ticker CVKD.
The company is offering shares at an expected price of $5.00 per share with an insider lock-up period of 180 days ending on July 19, 2023.
See also: Benzinga IPO Calendar
About Cadrenal Therapeutics, Inc
Cadrenal Therapeutics, Inc is focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease and atrial fibrillation (irregular heartbeat) or AFib
See also: Benzinga’s Most Shorted Stocks
This article was generated by Benzinga’s automated content engine and reviewed by an editor.